Compare PECO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | DNTH |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | 2010 | 2018 |
| Metric | PECO | DNTH |
|---|---|---|
| Price | $40.43 | $83.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 18 |
| Target Price | $43.46 | ★ $139.25 |
| AVG Volume (30 Days) | ★ 968.8K | 723.8K |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 74.51 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $726,594,000.00 | $2,036,000.00 |
| Revenue This Year | $5.19 | $22.80 |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | $38.48 | ★ N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $34.49 | $35.84 |
| 52 Week High | $44.38 | $117.88 |
| Indicator | PECO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 44.01 |
| Support Level | $38.78 | $79.54 |
| Resistance Level | $40.49 | $91.36 |
| Average True Range (ATR) | 0.69 | 4.84 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 42.91 | 19.24 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.